Form 4: Gilead Sciences Executive Reports Stock Transactions

Deborah H. Telman, EVP, Corporate Affairs & GC of Gilead Sciences, reports transactions involving common stock and restricted stock units.

Summary

• On April 25, 2025, Deborah H. Telman, EVP, Corporate Affairs & GC of Gilead Sciences, executed transactions involving the company's stock.
• Telman acquired 514 shares of common stock through the vesting of restricted stock units.
• She also disposed of 158 shares to cover tax obligations at a price of $103.17 per share.
• Following these transactions, Telman directly owns 36,918 shares of Gilead Sciences common stock.
• Telman also holds 31,702 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing, reflecting standard stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, as required by the SEC. It provides transparency into the trading activities of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives.
• Similar filings are made by executives at companies like Amgen (AMGN), Pfizer (PFE), and Johnson & Johnson (JNJ) when they trade their company's stock.
• The information disclosed is consistent with regulatory requirements for insider trading transparency.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• The filing provides transparency to shareholders regarding executive stock ownership.

Key Dates

Keywords

Gilead Sciences, GILD, Deborah H. Telman, Form 4, Stock Transaction, Restricted Stock Units, Beneficial Ownership, EVP, Corporate Affairs & GC